title: Role of xanthine oxidase and eicosanoids in development of pancreatic ischemia-reperfusion injury.
abstract: The implication of different eicosanoids and oxygen free radicals in the development of pancreatic injury after an ischemia-reperfusion process has been evaluated. For this purpose we have compared the effect of allopurinol and indomethacin administration on the pancreatic levels of eicosanoids in a rat model of pancreatic ischemia-reperfusion. After 60 min of pancreatic ischemia and 2 h of reperfusion, significant increases in 6-keto-PGF1 alpha, PGE2, and LTB4 in pancreas tissue were detected. Allopurinol before the ischemic period reduced 6-keto-PGF1 alpha, PGE2, and LTB4 levels to the range of basal values, while prior indomethacin treatment significantly reduced 6-keto-PGF1 alpha and PGE2 levels, with LTB4 remaining unmodified. Increased postischemic plasma lipases were also significantly reduced by allopurinol to the range of sham-operated animals whereas indomethacin did not modify these levels. The data suggest a role for lipoxygenase metabolites in the development of pancreatic injury and the importance of the enzyme xanthine oxidase as an inductor of eicosanoid biosynthesis.
authors.affiliation: Department of Medical Bioanalysis, CID, CSIC, Barcelona, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Hotter
authors.forename: D
authors.initials: D
authors.lastname: Closa
authors.forename: E
authors.initials: E
authors.lastname: Gelpí
authors.forename: N
authors.initials: N
authors.lastname: Prats
authors.forename: J
authors.initials: J
authors.lastname: Roselló-Catafau
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis / Q000502:physiology*; D000493:Allopurinol / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D015415:Biomarkers; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015232:Dinoprostone / Q000096:biosynthesis / Q000502:physiology*; D005609:Free Radicals; D007213:Indomethacin / Q000494:pharmacology / Q000627:therapeutic use; D007511:Ischemia / Q000378:metabolism*; D007975:Leukotriene B4 / Q000096:biosynthesis / Q000502:physiology*; D008049:Lipase / Q000097:blood; D008084:Lipoxygenase / Q000378:metabolism; D008297:Male; D018384:Oxidative Stress; D010179:Pancreas / Q000098:blood supply* / Q000201:enzymology; D010195:Pancreatitis / Q000209:etiology / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D015427:Reperfusion Injury / Q000378:metabolism* / Q000517:prevention & control; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: D015415:Biomarkers; D016861:Cyclooxygenase Inhibitors; D005609:Free Radicals; D017382:Reactive Oxygen Species; D007975:Leukotriene B4; D015121:6-Ketoprostaglandin F1 alpha; D000493:Allopurinol; D008084:Lipoxygenase; D014969:Xanthine Oxidase; D008049:Lipase; D015232:Dinoprostone; D007213:Indomethacin